Trends in Immunotherapy

Editorial

Combined immunotherapy and countermeasures for immune-related adverse events

Downloads

https://doi.org/10.24294/ti.v6.i1.1384
Kita, H. (2022). Combined immunotherapy and countermeasures for immune-related adverse events. Trends in Immunotherapy, 6(1). https://doi.org/10.24294/ti.v6.i1.1384
Volume 6 Issue 1 (2022)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Hideo Kita
    Department of Respiratory Medicine, Takatsuki Red Cross Hospital

   

Keywords:

Combined Immunotherapy Countermeasures Immune-related Adverse Events Immune Checkpoint Inhibitors Nivolumab Ipilimumab

References

  1. Furukawa F. The Nobel prize in pysiology or mdicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trends in Immunotherapy 2018; 2(1). doi: 10.24294/ti.v2.i3.1065
  2. Seidel JA, Otsuka A, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and lmitations. Trends in Immunotherapy 2017; 1(1): 2–9. doi: 10.24294/ti.v1.i1.20
  3. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends in Immunotherapy 2020; 4(1): 18–26. doi: 10.24294/ti.v4.i1.606
  4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine 2019; 381(16): 1535–1546. doi: 10.1056/NEJMoa1910836
  5. Motzer RJ, Tannier NM, McDermott DF, et al. Nivolumab plus ipilimumab versus snitinib in advanced renal-cell carcinoma. New England Journal of Medicine 2018; 378: 1277–1290. doi: 10.1056/NEJMoa1712126
  6. Takayasu K, Kinoshita H, Muguruma K. Durable complete response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma [in Press]. Trends in Immunotherapy 2022; 6(1) .
  7. Nomizo T, Yamamoto H, Murayama T, et al. Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer [in Press]. Trends in Immunotherapy 2022; 6(1).
  8. Hamatake K, Kojima K. Initiatives for immune-related adverse events by the outpatient pharmacist clinic. Trends in Immunotherapy 2022; 6(1): 3–6.